Ptc Therapeutics, Inc. PTCT
We take great care to ensure that the data presented and summarized in this overview for PTC THERAPEUTICS, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding PTCT
View all-
Vanguard Group Inc Valley Forge, PA9.18MShares$523 Million0.01% of portfolio
-
Black Rock Inc. New York, NY7.77MShares$443 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY7.39MShares$421 Million5.44% of portfolio
-
Armistice Capital, LLC New York, NY6.38MShares$363 Million4.07% of portfolio
-
Wellington Management Group LLP Boston, MA4.79MShares$273 Million0.04% of portfolio
-
Toronto Dominion Bank Toronto, Ontario, A63.29MShares$187 Million0.24% of portfolio
-
Camber Capital Management LP Boston, MA3.2MShares$182 Million3.34% of portfolio
-
State Street Corp Boston, MA2.71MShares$154 Million0.0% of portfolio
-
Janus Henderson Group PLC London, X02.33MShares$133 Million0.06% of portfolio
-
Geode Capital Management, LLC Boston, MA1.8MShares$102 Million0.01% of portfolio
Latest Institutional Activity in PTCT
Top Purchases
Top Sells
About PTCT
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.
Insider Transactions at PTCT
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Mar 17
2025
|
Eric Pauwels CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Direct |
6,762
-2.19%
|
$378,672
$56.96 P/Share
|
Mar 14
2025
|
Eric Pauwels CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Direct |
4,458
-5.32%
|
$245,190
$55.19 P/Share
|
Mar 13
2025
|
Stephanie Okey |
SELL
Open market or private sale
|
Direct |
5,000
-36.06%
|
$270,000
$54.0 P/Share
|
Mar 12
2025
|
Mark Elliott Boulding EXEC. VP AND CLO |
SELL
Open market or private sale
|
Direct |
15,521
-6.73%
|
$822,613
$53.27 P/Share
|
Mar 12
2025
|
Mark Elliott Boulding EXEC. VP AND CLO |
BUY
Exercise of conversion of derivative security
|
Direct |
15,521
+6.14%
|
$512,193
$33.02 P/Share
|
Mar 11
2025
|
Mark Elliott Boulding EXEC. VP AND CLO |
SELL
Open market or private sale
|
Direct |
7,381
-3.4%
|
$391,193
$53.01 P/Share
|
Mar 11
2025
|
Mark Elliott Boulding EXEC. VP AND CLO |
BUY
Exercise of conversion of derivative security
|
Direct |
7,381
+3.26%
|
$243,573
$33.02 P/Share
|
Mar 10
2025
|
Mark Elliott Boulding EXEC. VP AND CLO |
SELL
Open market or private sale
|
Direct |
68,039
-12.57%
|
$3,538,028
$52.89 P/Share
|
Mar 10
2025
|
Mark Elliott Boulding EXEC. VP AND CLO |
BUY
Exercise of conversion of derivative security
|
Direct |
68,039
+13.74%
|
$2,041,170
$30.58 P/Share
|
Mar 04
2025
|
Allan Steven Jacobson |
SELL
Open market or private sale
|
Direct |
1,230
-6.04%
|
$62,730
$51.52 P/Share
|
Feb 20
2025
|
Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER |
SELL
Open market or private sale
|
Indirect |
34
-0.57%
|
$1,700
$50.12 P/Share
|
Feb 20
2025
|
Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER |
SELL
Open market or private sale
|
Direct |
1,578
-1.55%
|
$78,900
$50.12 P/Share
|
Feb 20
2025
|
Mark Elliott Boulding EXEC. VP AND CLO |
SELL
Open market or private sale
|
Direct |
1,614
-1.53%
|
$80,700
$50.12 P/Share
|
Feb 20
2025
|
Lee Scott Golden EVP & CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
962
-1.24%
|
$48,100
$50.12 P/Share
|
Feb 20
2025
|
Matthew B. Klein CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
3,895
-1.39%
|
$194,750
$50.12 P/Share
|
Feb 20
2025
|
Eric Pauwels CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Direct |
1,567
-1.83%
|
$78,350
$50.12 P/Share
|
Feb 20
2025
|
Pierre Gravier CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,167
-1.54%
|
$58,350
$50.12 P/Share
|
Feb 20
2025
|
Christine Marie Utter SVP, CHIEF ACCOUNTING OFFICER |
SELL
Open market or private sale
|
Direct |
878
-1.38%
|
$43,900
$50.12 P/Share
|
Feb 19
2025
|
Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER |
SELL
Open market or private sale
|
Indirect |
34
-0.57%
|
$1,700
$50.1 P/Share
|
Feb 19
2025
|
Neil Gregory Almstead CHIEF TECHNICAL OPS OFFICER |
SELL
Open market or private sale
|
Direct |
1,300
-1.26%
|
$65,000
$50.1 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 226K shares |
---|---|
Exercise of conversion of derivative security | 320K shares |
Open market or private sale | 397K shares |
---|---|
Bona fide gift | 1.65K shares |